Researchers develop new strategy to limit side effects of stem cell transplants

August 15, 2016
Fluorescence microscopy of mouse lymph nodes reveals that treatment with STAR2 (right) increases the number of regulatory T cells, which express a protein called Foxp3 (red). Credit: Chopra et al., 2016

Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants. The researchers describe the successful application of their strategy in mice in "Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion," which will be published online August 15 ahead of issue in The Journal of Experimental Medicine.

Bone marrow transplants can cure types of leukemia and lymphoma because derived from the donor's bone marrow can develop into immune cells capable of killing the patient's . But the donor-derived immune cells may also attack the transplant recipient's healthy tissues, producing the diverse and sometimes severe symptoms of GvHD. One approach to avoiding GvHD is to co-transplant large numbers of regulatory T cells (T reg cells), that can suppress the donor cells' effects on healthy tissue while maintaining their ability to kill tumor cells. This approach is challenging, however, because the T reg cells must first be isolated from the donor's peripheral blood or bone marrow and then cultivated in the laboratory to produce sufficient numbers for transplantation.

A team of researchers led by Andreas Beilhack and Harald Wajant of the University Hospital W?rzburg devised an alternative way to prevent GvHD in mice, developing a protein called STAR2 that can stimulate the formation of the transplant recipient's own T reg cells in vivo. Pretreating mice with STAR2 protected them from developing GvHD after immune cell transplantation. The donor-derived cells retained their ability to kill the recipient's lymphoma cells, however.

STAR2 works by specifically binding to a cell surface protein called TNFR2, activating a signaling pathway that increases the number of T reg cells. Beilhack and colleagues found that a slightly modified version of STAR2 has a similar effect on human T reg cells, suggesting that the approach could also prevent GvHD in leukemia and lymphoma patients after or hematopoietic stem cell transplants. "Furthermore, this strategy may be beneficial for other pathological settings in which elevated numbers of regulatory T cells are desirable, such as autoimmune diseases and solid organ transplantation," Beilhack says.

Explore further: Immune cell subset is associated with development of gastrointestinal GVHD after HSCT

More information: Chopra, M., et al. 2016. J. Exp. Med. DOI: 10.1084/jem.20151563

Related Stories

Less toxic bone marrow transplants on horizon

August 10, 2016

Bone marrow transplants that do not require dangerous and often toxic chemotherapy could soon be possible, US researchers said Wednesday after seeing initial success with experiments on mice.

Recommended for you

Survivors of childhood brain tumors have increased body fat

March 24, 2017

McMaster University researchers have discovered that while survivors of childhood brain tumours have a similar Body Mass Index (BMI) to healthy children with no cancer, they have more fat tissue overall, and especially around ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.